ABSTRACT
Adult T cell leukemia/lymphoma [ATLL] is an aggresive malignancy which may occur in human T lymphotropic virus [HTLVl] infected persons. HTLV1 is endemic in Khorasan with prevalence of 2.3% in general population. Since specific cutaneous manifestations of lymphoma may occur in a significant number of patients, we studied ATLL patients in Mashhad In this descriptive study the demographic and clinical data of 23 patient suffering from ATLL who were admitted in hematology and dermatology departments of Ghaem Hospital, during 1995-2004 and had specific cutaneous lesions confirmed histopathologically with atypical lymphocytes in skin lesions, were recorded and analyzed. Eleven patients were male and 12 were female. The mean age of patients was 48.17 +/- 14.1 years. Birth places of over 85% of cases were north of Khorasan. The most common types of specific skin lesions were maculopapular rash in 11 cases [47.8%] and papular lesions in 4 cases [17.4%]. Other lesions included plaque, icthyosis like, erythroderma, tumor, and nodular lesions. In most of patients [56.5%] the skin lesions were generalized The most common type of specific skin lesions in ATLL was maculopapular rash especially with generalized distribution. Other types of specific skin lesions in order of frequency were papule, plaque, icthyosis like, nodule, tumor and erythroderma
Subject(s)
Humans , Male , Female , Leukemia, T-Cell/diagnosis , Lymphoma, T-Cell, Cutaneous , Signs and Symptoms , Skin Manifestations/diagnosis , Skin Manifestations/pathologyABSTRACT
Cutaneous leishmaniasis is an important skin parasitic disease. Ideal treatment is not found yet and seeking for proper drugs continues. Comparison of the efficacy of fluconazole with systemic Glucantime in patients with acute cutaneous leishmanisis in Ghaem Hospital in Mashhad in 2002 .During one year of study, all patients with cutaneous leishmaniasis were divided to two groups. Thirty-one patients were treated with oral fluconazole [100 mg twice a day] for 6 weeks and 29 patients were treated with intramuscular Glucantime [20 mgSb/kg] for 21 days. Both groups were evaluated 3 and 6 weeks after onset of treatment. T test and chi-square test were used for statistical analyses and P<0.05 was considered as significant. Six weeks after begining of treatment, clinical cure, improvement and failure were observed in 4 [12.9%],11 [35.5%] and 16 [51.5%] of patients treated with fluconazole, respectively. These figures were 11[37.9%], 10 [34.6%] and 8 [21.5%] of patients treated with Glucantime, respectively [P>0.05]. It seems that efficacy of fluconazole in acute cutaneous leishmaniasis is lower than Glucantime. A larger clinical trial is recommended